Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
DENVER, Feb. 15, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) announced today that the Company will release its fourth quarter and full-year 2016 financial results on Friday, March 3, 2017, before the opening of the U.S. financial markets.
Daniel E. Greenleaf, President and Chief Executive Officer, and Jeffrey M. Kreger, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:
| Date | Friday, March 3, 2017 | ||
| Time | 9:00 a.m. EST | ||
| Toll free (U.S.) | (888) 372-9592 | ||
| Webcast (live and replay) | www.bioscrip.com | ||
A replay of the conference call will be available for one week after the call's completion by dialing (855) 859-2056 (US) and entering conference call ID number 5266355.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Investor Contacts: Jeffrey M. Kreger Chief Financial Officer T: (720) 697-5200 [email protected] David Clair ICR, Inc. T: (646) 277-1266 [email protected]
